Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence

Tenofovir alafenamide (TAF), a novel prodrug of tenofovir was developed to deliver enhanced antiviral potency and reduced systemic toxicities by more efficient intracellular delivery of the active metabolite tenofovir disphosphate than tenofovir disoproxil fumarate (TDF). In two randomized, double-b...

Descripción completa

Detalles Bibliográficos
Autores principales: Byrne, Ruth, Carey, Ivana, Agarwal, Kosh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048601/
https://www.ncbi.nlm.nih.gov/pubmed/30034532
http://dx.doi.org/10.1177/1756284818786108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048601/
https://www.ncbi.nlm.nih.gov/pubmed/30034532
http://dx.doi.org/10.1177/1756284818786108

Ejemplares similares